其他風濕疾病合併間質性肺病之治療建議：類風濕關節炎、乾燥症、多發性肌炎及皮肌炎

10.6666/ClinMed.202205_89(5).0049

賴建志；孫易暄；蔡長祐

類風濕關節炎（rheumatoid arthritis, RA） ； 乾燥症（Sjögren's syndrome） ； 多發性肌炎及皮肌炎（Polymyositis, dermatomyositis） ； 間質性肺病（interstitial lung disease, ILD） ； 漸進式纖維化間質性肺病（progressive fibrosing interstitial lung diseases, PF-ILD）

臨床醫學月刊

89卷5期（2022 / 05 / 27）

298 - 303

繁體中文

類風濕關節炎、乾燥症、多發性肌炎及皮肌炎常合併間質性肺病，針對有症狀之患者，以及肺功能或影像快速纖維化病灶進展之患者，應早期積極治療。在開立針對間質性肺病之藥物治療前，須先排除惡性腫瘤、風濕病修飾藥物引起之過敏性肺炎，以及長期免疫抑制造成的感染性肺炎。越來越多抗發炎藥物與抗纖維化藥物，在不同之風濕疾病，皆陸續證實其療效。本文將逐一介紹類風濕關節炎、乾燥症、多發性肌炎及皮肌炎合併間質性肺病最新之治療證據，提供臨床醫師作為治療建議。

1. Bongartz, T,Nannini, C,Medina-Velasquez, YF(2010).Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study.Arthritis Rheumatism,62,1583-1591.
2. Bowman, SJ,Everett, CC,O´Dwyer, JL(2017).Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren’s Syndrome.Arthritis Rheumatol,69,1440-1450.
3. Brito, Y,Glassberg, MK,Ascherman, DP(2017).Rheumatoid Arthritis-Associated Interstitial Lung Disease: Current Concepts.Curr Rheumatol Rep,19,79.
4. Chen, M-H,Chen, C-K,Chou, H-P(2016).Rituximab therapy in primary Sjögren’s syndrome with interstitial lung disease: a retrospective cohort study.Clin Exp Rheumatol,34,1077-1084.
5. Cottin, V,Hirani, NA,Hotchkin, DL(2018).Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.European Resp,27,180076.
6. Flaherty, KR,Wells, AU,Cottin, V(2019).Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.New Engl J Med,381,1718-1727.
7. Furuya, H,Nakajima, M,Ikeda, K(2021).Prognosis and treatment of myositis-associated severe interstitial lung disease: A descriptive study using a nation-wide inpatient database in Japan.Arthrit Care Res
8. Gottenberg, J-E,Cinquetti, G,Larroche, C(2013).Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry.Ann Rheum Dis,72,1026-1031.
9. Kelly, CA,Nisar, M,Arthanari, S(2020).Rheumatoid arthritis related interstitial lung disease - improving outcomes over 25 years: a large multicentre UK study.Rheumatology,60,1882-1890.
10. Luppi, F,Sebastiani, M,Silva, M(2020).Interstitial lung disease in Sjögren’s syndrome: a clinical review.Clin Exp Rheumatol,38(126),291-300.
11. Mena-Vázquez, N,Godoy-Navarrete, FJ,ManriqueArija, S(2021).Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis.Clin Rheumatol,40,133-142.
12. Romero-Bueno, F,Campo, PD(2020).Recommendations for the Treatment of Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease.Semin Arthritis Rheu,50,776-790.
13. Saketkoo, LA,Espinoza, LR(2008).Rheumatoid Arthritis Interstitial Lung Disease: Mycophenolate Mofetil as an Antifibrotic and Disease Modifying Antirheumatic Drug.Arch Intern Med,168,1718-1719.
14. Sidhu, HS,Bhatnagar, G,Bhogal, P(2011).Imaging Features of the Pleuropulmonary Manifestations of Rheumatoid Arthritis: Pearls and Pitfalls.J Clin Imaging Sci,1,32.
15. Tsuji, H,Nakashima, R,Hosono, Y(2020).Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation Associated Gene 5-Positive Dermatomyositis.Arthritis Rheumatol,72,488-498.
16. Vassallo, R,Matteson, E,Thomas, CF(2002).Clinical Response of Rheumatoid Arthritis-Associated Pulmonary Fibrosis to Tumor Necrosis Factor-αInhibition.Chest,122,1093-1096.
17. Wells, AU,Flaherty, KR,Brown, KK(2020).Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo controlled, parallel-group trial.Lancet Respir Medicine,8,453-460.
18. Ye, S,Chen, X,Lu, X(2007).Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.Clin Rheumatol,26,1647-1654.
19. Yusof, MYM,Kabia, A,Darby, M(2017).Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years´experience at a single centre.Rheumatology,56,1348-1357.

1. 謝懷棣,謝孟蓁,楊政議,彭芷瑜,留美萍,李麗紅,李品萱(2023)。修格蘭氏症候群病人之求醫經驗。護理雜誌，70(5)，36-43。